Clinical Trial Update: Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of Cold-FX (CVT-E002) in preventing upper respiratory tract infections in healthy adults has completed. The sponsor was CV…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Respiratory Tract Infection

Drugs mentioned

• COLD-fX

Snippet

Sponsor: CV Technologies | Conditions: Upper Respiratory Infection | Phase 3 | Status: COMPLETED